1 |
Tralokinumab |
Tralokinumab |
[1] D09979 D09979 💬 |
IL13 [1] IL13 💬 |
Asthma [8] Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation |
085 [2] 85, 97 💬 |
2 |
Tralokinumab cohort 1 |
Tralokinumab |
[1] D09979 D09979 💬 |
IL13 [1] IL13 💬 |
Asthma [8] Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation |
085 [1] 85 💬 |
3 |
Tralokinumab cohort 2 |
Tralokinumab |
[1] D09979 D09979 💬 |
IL13 [1] IL13 💬 |
Asthma [8] Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation |
085 [1] 85 💬 |
4 |
Tralokinumab is a human recombinant monoclonal antibody (mab) of the subclass that specifically binds human il-13, blocking interactions with the il-13 receptor |
Tralokinumab |
[1] D09979 D09979 💬 |
IL13 [1] IL13 💬 |
Asthma [8] Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation |
085 [1] 85 💬 |